- Home
- NIPG vs SERA Comparison
NIPG vs SERA Comparison
Compare NIPG & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- SERA
- Stock Information
- Founded
- NIPG 2014
- SERA 2008
- Country
- NIPG Sweden
- SERA United States
- Employees
- NIPG N/A
- SERA N/A
- Industry
- NIPG
- SERA Precision Instruments
- Sector
- NIPG
- SERA Health Care
- Exchange
- NIPG NYSE
- SERA Nasdaq
- Market Cap
- NIPG 212.9M
- SERA 208.7M
- IPO Year
- NIPG 2024
- SERA 2021
- Fundamental
- Price
- NIPG $2.73
- SERA $4.12
- Analyst Decision
- NIPG Strong Buy
- SERA
- Analyst Count
- NIPG 1
- SERA 0
- Target Price
- NIPG $12.00
- SERA N/A
- AVG Volume (30 Days)
- NIPG 166.3K
- SERA 150.9K
- Earning Date
- NIPG 03-04-2025
- SERA 03-19-2025
- Dividend Yield
- NIPG N/A
- SERA N/A
- EPS Growth
- NIPG N/A
- SERA N/A
- EPS
- NIPG N/A
- SERA N/A
- Revenue
- NIPG $84,449,477.00
- SERA $94,000.00
- Revenue This Year
- NIPG $7.65
- SERA N/A
- Revenue Next Year
- NIPG $14.38
- SERA $3,081.82
- P/E Ratio
- NIPG N/A
- SERA N/A
- Revenue Growth
- NIPG 6.07
- SERA N/A
- 52 Week Low
- NIPG $2.69
- SERA $3.84
- 52 Week High
- NIPG $17.76
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- SERA 31.08
- Support Level
- NIPG N/A
- SERA $3.89
- Resistance Level
- NIPG N/A
- SERA $4.46
- Average True Range (ATR)
- NIPG 0.00
- SERA 0.43
- MACD
- NIPG 0.00
- SERA -0.00
- Stochastic Oscillator
- NIPG 0.00
- SERA 10.22
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a esports organization with operations across Asia, Europe and South America. It operate two esports brands: Ninjas in Pyjamas and eStar Gaming. Ninjas in Pyjamas, is a PC or console esports brand. eStar Gaming, is a mobile esports brand. The company has two reportable segments, including PRC and other entities, and Ninjas in Pyjamas. Key revenue is generated from PRC and other entities.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.